Temporal dynamics of RAS mutations in circulating tumor DNA in metastatic colorectal cancer: clinical significance of mutation loss during treatment.

Kenta IguchiManabu ShiozawaMamoru UchiyamaMasahiro AsariKoji NumataYasushi RinoAya Saito

Published in: Journal of cancer research and clinical oncology (2024)

The rate of ctDNA mutation loss in patients with RAS-MT mCRC decreases over time. Therefore, using a ctDNA RAS assay early in treatment will assist in challenging the use of EGFR regimens.

Keyphrases

circulating tumor
metastatic colorectal cancer
wild type
cell free
circulating tumor cells
small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
high throughput
replacement therapy
smoking cessation
single molecule